Merck’s KEYTRUDA® (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1
Go back to Merck’s KEYTRUDA® (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1| Merck & Co. (NYSE: MRK) | Delayed: 118.94 +3.46 (3.00%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $115.48 | 52 Week High | $65.46 | |||
| Open | $116.53 | 52 Week Low | $47.97 | |||
| Day High | $119.40 | P/E | 80.91 | |||
| Day Low | $116.53 | EPS | $1.47 | |||
| Volume | 5,227,433 | |||||
